Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

New Tick-Borne Disease Threatens Primarily Immune Suppressed Persons

By LabMedica International staff writers
Posted on 16 Jun 2014
A newly discovered tick-borne bacterium known as Candidatus Neoehrlichia mikurensis has been implicated in six cases of the disease in Sweden.

The bacterium, which is spread by rodents and ticks mainly in Asia and Europe, including Sweden, has been found in 19 cases worldwide and is primarily a risk for people who are already sick and who are receiving immunosuppressive drugs.

Scientists at the University of Gothenburg (Sweden) working with their European colleagues compiled clinical and laboratory data from 11 patients with hematological malignances or autoimmune diseases who were diagnosed with Ca. N. More...
mikurensis infection in Europe from 2010 to 2013. The patients had a median age of 67, were mostly male (8/11), and resided in Sweden, Switzerland, Germany, and the Czech Republic. All but one had ongoing or recent immune suppressive treatment and a majority were splenectomized (8/11).

The most abnormal laboratory findings among all the patients was elevation of the acute phase reactant C-reactive protein in serum, with levels ranging from 4- to 74-fold higher than the cutoff level. Leukocytosis with neutrophilia and anemia were also typical findings. About half of the patients had at some point raised levels of lactate dehydrogenase in serum and hyponatremia, respectively. Lowered platelet counts and elevated transaminase concentrations were rare findings.

The diagnosis of Ca. Neoehrlichia infection was in all cases based on pan-bacterial polymerase chain reaction (PCR) analysis of segments of the 16S ribosomal ribonucleic acid (rRNA) gene followed by sequence and homology analyses. Once neoehrlichiosis has been diagnosed, the patients recover completely after treatment with antibiotics. Physicians within the fields of rheumatology, hematology, oncology, and infectious diseases should be aware of this new infectious agent and their attention drawn to patients with suspected recurrence of the underlying autoimmune or hematologic disease where the clinical picture is atypical.

Christine Wennerås, MD, PhD, the senior author of the study said, “The bacterium cannot be grown in culture, and this means that it is not picked up in routine diagnostic procedures. Furthermore, the symptoms are deceptive. Several patients, for example, have been affected by blood clots in the leg or the blood vessels in the head, and this has not been coupled to an infectious cause. Other typical symptom such as fever, muscle pain and joint pain can be caused also by the patient’s underlying disease. We know very little about how the infection affects otherwise healthy people who are not taking immunosuppressive drugs.” The study was published online on March 18, 2014, in the journal Clinical Infectious Diseases.

Related Links:

University of Gothenburg



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.